` I4P (Intercept Pharmaceuticals Inc) vs DAX Index Comparison - Alpha Spread

I
I4P
vs
D
DAX Index

Over the past 12 months, I4P has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +22% growth.

Stocks Performance
I4P vs DAX Index

Loading
I4P
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
I4P vs DAX Index

Performance Gap Between I4P and GDAXI
HIDDEN
Show

Performance By Year
I4P vs DAX Index

Loading
I4P
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Intercept Pharmaceuticals Inc vs Peers

DAX Index
I4P
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Intercept Pharmaceuticals Inc
Glance View

Market Cap
732.5m EUR
Industry
Biotechnology

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 437 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.

I4P Intrinsic Value
Not Available
Back to Top